Laurus Labs Q1 FY27: Revenue Soars 29% to ₹2,026 Cr, EBITDA Jumps 66%
Laurus Labs reported a 29% YoY revenue growth to ₹2,026 crore in Q1 FY27, driven by CDMO and Affordable Medicines segments. EBITDA surged 66% to ₹644 crore with margins at 31.8%. Net profit increased 126% to ₹368 crore. CAPEX was 19% of sales.
The substantial increase in revenue, EBITDA, and net profit, coupled with strategic investments in R&D and manufacturing, is expected to have a significant positive impact on investor confidence and the company's market position.
The company reported strong year-on-year growth in revenue, EBITDA, and net profit, along with improved margins and significant R&D investment, indicating positive financial performance and future growth potential.
Laurus Labs Limited has announced its financial results for the first quarter of FY27, reporting a significant 29% year-on-year increase in revenue, reaching ₹2,026 crore. This growth was primarily driven by robust performance in the Contract Development and Manufacturing Organization (CDMO) segment, supported by sustained momentum in the Affordable Medicines business, particularly in Finished Dosage Forms (FDF).
The company also reported a substantial 66% year-on-year increase in EBITDA, which stood at ₹644 crore. EBITDA margins improved by 700 basis points to 31.8%, attributed to a favorable product mix and enhanced operational leverage. Gross margins also expanded by 330 basis points to 62.7% due to a better divisional mix.
Net profit saw a significant surge of 126% year-on-year, reaching ₹368 crore. Earnings Per Share (EPS) grew by 127% to ₹6.8. Research and Development (R&D) expenditure increased by 74% to ₹118 crore, reflecting ongoing development efforts in building advanced biologics infrastructure, including gene therapy and ADC capabilities.
Laurus Labs continued its investment in manufacturing network expansion and niche capabilities, with overall Capital Expenditure (CAPEX) at 19% of sales. The company highlighted its commitment to its long-term growth strategy, focusing on integrated solutions, advanced biologics, and expanding its CDMO and Affordable Medicines businesses.
What to do with a filing like this
Laurus Labs Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Laurus Labs Limited. Read the original for the full detail.